Trial · NCT03416179
Results by group625
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 625
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Intensive Study: Overall Survival (OS) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 17.3 | 95% Confidence Interval 15.2 to 18.5 | months | |
| Intensive Study: Overall Survival (OS) | Intensive Study: Placebo + Cytarabine + Daunorubicin | 20.4 | 95% Confidence Interval 17.6 to NA | months | |
| Non-intensive Study: Overall Survival (OS) | Non-intensive Study: Glasdegib + Azacitidine | 10.3 | 95% Confidence Interval 7.7 to 12.4 | months | |
| Non-intensive Study: Overall Survival (OS) | Non-intensive Study: Placebo + Azacitidine | 10.6 | 95% Confidence Interval 8.4 to 13.3 | months | |
Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 17.41 | 95% Confidence Interval 12.17 to 22.66 | Percentage of participants | |
Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire | Intensive Study: Placebo + Cytarabine + Daunorubicin | 17.24 | 95% Confidence Interval 12.05 to 22.44 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12 | Non-intensive Study: Glasdegib + Azacitidine | 11.66 | 95% Confidence Interval 6.73 to 16.58 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12 | Non-intensive Study: Placebo + Azacitidine | 15.43 | 95% Confidence Interval 9.87 to 21.00 | Percentage of participants | |
| Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 5.0 | 95% Confidence Interval 2.4 to 9.0 | Percentage of participants | |
| Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg) | Intensive Study: Placebo + Cytarabine + Daunorubicin | 5.4 | 95% Confidence Interval 2.7 to 9.5 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg) | Non-intensive Study: Glasdegib + Azacitidine | 1.8 | 95% Confidence Interval 0.4 to 5.3 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg) | Non-intensive Study: Placebo + Azacitidine | 0.6 | 95% Confidence Interval 0.0 to 3.4 | Percentage of participants | |
| Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 49.3 | 95% Confidence Interval 42.1 to 56.4 | Percentage of participants | |
| Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg) | Intensive Study: Placebo + Cytarabine + Daunorubicin | 47.3 | 95% Confidence Interval 40.3 to 54.4 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg) | Non-intensive Study: Glasdegib + Azacitidine | 19.6 | 95% Confidence Interval 13.8 to 26.6 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg) | Non-intensive Study: Placebo + Azacitidine | 13.0 | 95% Confidence Interval 8.2 to 19.1 | Percentage of participants | |
| Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi) | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 1.5 | 95% Confidence Interval 0.3 to 4.3 | Percentage of participants | |
| Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi) | Intensive Study: Placebo + Cytarabine + Daunorubicin | 5.4 | 95% Confidence Interval 2.7 to 9.5 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi) | Non-intensive Study: Glasdegib + Azacitidine | 2.5 | 95% Confidence Interval 0.7 to 6.2 | Percentage of participants | |
| Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi) | Non-intensive Study: Placebo + Azacitidine | 4.9 | 95% Confidence Interval 2.2 to 9.5 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03416179/results